Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03881059 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 203
- Enrollment target
NCT03881059: Completed Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT03881059 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 203 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03881059, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 203 participants
- Enrollment target
Study Summary
The main purpose of study is to assess the dose-response relationship of BMS-986165 (Dose A or Dose B once daily \[QD\]) at Week 16 in the treatment of participants with active PsA.
Primary Outcome
A participant is considered an ACR 20 responder if the following three conditions are met: 1) ≥ 20% improvement from baseline in the number of tender joints (68 joint count). 2) ≥ 20% improvement from baseline in the number of swollen joints (66 joint count). 3) ≥ 20% improvement from baseline in at least 3 of the following 5 domains: o Subject Global Assessment of disease activity o Physician Global Assessment of psoriatic arthritis o Subject Global Assessment of pain o Health Assessment Questi
Interventions
- DRUG Ustekinumab
- OTHER BMS-986165 Placebo
- DRUG BMS-986165 Dose A
- DRUG BMS-986165 Dose B
- OTHER Ustekinumab Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2021-01-27 |
| Phase | Phase 2 |
What the finished NCT03881059 record still lists
NCT03881059 is an interventional study that assigns participants to a tested intervention. The registered 203 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% higher).
The record links to 0 conditions, and to 5 interventions - of which Ustekinumab is the first listed.
NCT03881059 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03881059 about?
NCT03881059 is a clinical study titled "Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)". The main purpose of study is to assess the dose-response relationship of BMS-986165 (Dose A or Dose B once daily \[QD\]) at Week 16 in the treatment of participants with active PsA.
What is the current status of trial NCT03881059?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 203 participants. The study started on 2019-04-01. Estimated completion is 2021-01-27.
What interventions are being tested in trial NCT03881059?
The interventions under investigation include: Ustekinumab (DRUG), BMS-986165 Placebo (OTHER), BMS-986165 Dose A (DRUG), BMS-986165 Dose B (DRUG), Ustekinumab Placebo (OTHER).
Who is sponsoring clinical trial NCT03881059?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03881059's enrollment target sits among peer trials
203 301st of 2000 higher than 1,700 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05652686 · 203 participants · Phase 1
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- NCT06063122 · 203 participants · NA
Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants
- NCT07031245 · 203 participants · NA
Evidence-Based Quality Improvement to Reduce VA Primary Care Burnout
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI